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Topical agents containing vitamin D3 (VD3) analogues such as calcipotriol, maxacalcitol and tacalcitol and
the combination of calcipotriol/betamethasone dipropionate (betamethasone) are prescribed for patients
with psoriasis. However, they are known to occasionally cause hypercalcemia, and the frequency of
hypercalcemia is suggested to vary according to the VD3 analogue used. In this study, to address the
reason for these differences, the calcemic effects of maxacalcitol-, calcipotriol- and calcipotriol/beta-
methasone-containing ointments in rats were evaluated. The serum calcium levels in rats treated with
ointments containing maxacalcitol, but not calcipotriol or calcipotriol/betamethasone, were signiﬁcantly
elevated, which is consistent with clinical observations. The serum concentration of VD3 analogue in rats
treated with ointments containing calcipotriol and calcipotriol/betamethasone was lower than that in
rats treated with maxacalcitol-containing ointment. Thus, the calcemic effects appear to be associated
with the systemic exposure of VD3 analogues in rats. To understand the mechanism underlying the
different systemic exposures of VD3 analogues, skin permeation and metabolic stability of VD3 analogues
were evaluated. The cumulative amount of calcipotriol permeated through rat skin was signiﬁcantly
lower than that of maxacalcitol. On the other hand, the metabolic clearance of calcipotriol in rat hepa-
tocytes was higher than that of maxacalcitol. Similar results were obtained using human skin and human
hepatocytes. The current study demonstrates that the lower calcemic effects of calcipotriol- and calci-
potriol/betamethasone-containing ointments are caused by the low systemic exposure of calcipotriol
according to low skin permeability and rapid hepatic elimination after topical application.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Topical agents containing active vitamin D3 (calcitriol, 1α, 25-
dihydroxyvitamin D3, VD3) analogues such as tacalcitol, calcipo-
triol and maxacalcitol are widely used for psoriasis therapy.
However, topical VD3 agents are occasionally known to cause hy-
percalcemia in patients with psoriasis. The efﬁcacy of these agents
is considered to be due to the induction of cell differentiation, the
inhibition of keratinocyte proliferation and the inhibition of cy-
tokine production in T cells, dendritic cells and keratinocytes
(Lovato et al., 2016) through vitamin D receptor, while the action
via vitamin D receptor is likely to result in an elevation of the
serum calcium level through modulating the expression levels of
transient receptor potential vanilloid 6, calbindin, osteocalcin, and
parathyroid hormone (Barthel et al., 2007; Jaaskelainen et al.,B.V. This is an open access article u
(A. Hosomi).2003; Naveh-Many and Silver, 1993; Saito and Harada, 2014).
Some reports have referred to the side effect of calcitriol ana-
logues in humans. Yamamoto et al. (2012) suggested that calci-
potriol is associated with lower serum calcium levels than ta-
calcitol and maxacalcitol. Moreover, animal studies have been
conducted following oral and intraperitoneal administration to
evaluate the calcemic potential of several VD3 analogues and the
calcemic mechanisms. However, there are few reports about the
calcemic actions/mechanisms after the transdermal application of
VD3 analogues, even though they are typically applied to the skin
for psoriasis treatment. Hence, the calcemic potencies after topical
application of VD3 ointments in clinical situations have not yet
been adequately investigated.
One reason for the calcemic effect is presumably due to the
high systemic exposure of VD3 analogues through transdermal
application (Baroni et al., 2008; Saito and Harada, 2014). In gen-
eral, the plasma concentration of a transdermal agent is depen-
dent on the balance between the skin permeation proﬁle and thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Therefore, in vitro studies using skin permeation with human skin
and metabolic stability in human hepatocytes of transdermal
agent are considered to be useful for predicting systemic exposure
in humans.
The present study aimed to clarify the relationship between the
systemic exposure of each VD3 analogue and the following calce-
mic effect in rats and demonstrate the differences in systemic
exposure among VD3 analogues according to the pharmacokinetic,
hepatic metabolism and skin permeation properties.2. Materials and methods
2.1. Chemicals, tissues and experimental animals
Calcipotriol was purchased from Tocris Bioscience (Bristol, UK).
Maxacalcitol was purchased from ChemScene, LLC. (Monmouth
Junction, NJ, USA). Simvastatin was purchased from Wako Pure
Chemical Industries (Osaka, Japan). Marketed ointment containing
either 25 μg/g of maxacalcitol (maxacalcitol ointment), 50 μg/g of
calcipotriol (calcipotriol ointment) or 50 μg/g of calcipotriol and
0.643 mg/g of betamethasone dipropionate (calcipotriol/beta-
methasone ointment) were used in this study. All other reagents
were commercially available. Male Hairless Wistar Yagi (HWY)/Slc
rats (5–6 weeks of age) were obtained from Japan SLC Inc. (Shi-
zuoka, Japan). Male Sprague Dawley rats (7–9 weeks of age) were
obtained from Charles River Laboratories Japan Inc. (Yokohama,
Japan). The experimental protocols were reviewed and approved
by the Kyowa Hakko Kirin Co., Ltd. Animal Care Committee in
accordance with the “Company Policy on the Care and Use of La-
boratory Animals”.
Rat (Lot. OJK) and human (Lot. HDI) cryopreserved hepatocytes
were purchased from Celsis In Vitro Technologies (Baltimore,
MD, USA). Excised human skin (female, Caucasian, 34–70 years
of age, Lot NO. TRA002001C014-C016, TRA002001C077-C079,
TRA002001C083-C084) was obtained from Biopredic International
(Saint-Gregoire, France) as frozen skin sets. The experimental
protocols were maintained according to the “Company Policy on
the Research Ethics Review Committee” by Kyowa Hakko Kirin Co.,
Ltd.
2.2. In vivo study
For the evaluation of the calcemic effects of VD3 analogue-
containing ointments after topical administration in rats, 200 mg
of each ointment was applied on the abdominal skin of HWY/Slc
rats anesthetized with isoﬂurane, followed by occlusion with Finn
Chamber discs (18 mm diameter; Bio Diagnostics Ltd.), Tegaderm
Transparent Dressing (3 M HealthCare) and bandages. In sham-
treated rats, Finn Chamber discs without any ointment was ap-
plied on the skin, and then occluded with Tegaderm Transparent
Dressing and bandages. Serum samples were collected from the
abdominal vein of the rats under isoﬂurane anesthesia at 1, 2, 6, 10,
24 and 48 h after the application of each ointment and were stored
at 20 °C until the measurement of calcipotriol, maxacalcitol and
calcium. The serum calcium concentration was measured using
the ortho-cresolphthalein complexone method with an automatic
analyzer (7180, Hitachi High Technologies).
For the pharmacokinetic study in rats, calcipotriol and max-
acalcitol were diluted in N, N-dimethylacetamide, and injected
into the femoral vein at 1 mg/kg under isoﬂurane anesthesia.
Plasma samples were obtained from the tail vein at 0.083, 0.25,
0.5, 1, 2, 4, 6 and 8 h after the dosing, and were stored at 20 °C.
The elimination half-life (t1/2), area under the plasma con-
centration-time curve from 0 to inﬁnity (AUC0-1) and total plasmaclearance (CLplasma) were calculated using the Phoenix WinNonlin
software program (version 6.1, Pharsight) based on a non-com-
partmental analysis.
2.3. In vitro metabolism
The metabolic stabilities of calcipotriol and maxacalcitol in rat
and human cryopreserved hepatocytes were evaluated. The in-
trinsic clearance was determined using the substrate depletion
approach. The study was performed using the methodologies de-
scribed in a previous report (Sohlenius-Sternbeck et al., 2010). In
brief, hepatocytes were diluted in William's medium E, and these
viabilities were determined using the Trypan blue exclusion
method. Hepatocytes were seeded into a 24-well plate at a cell
density of 1106 cells/ml. After pre-incubation for 15 min in an
incubator at 5% CO2, the metabolism was initiated by adding a
substrate to each well. The hepatocytes were incubated with VD3
analogues for 0, 15, 30, 60 and 90 min, and the reactions were
stopped by the addition of ice-cold acetonitrile containing internal
standard. The intrinsic metabolic clearance in hepatocytes (CLint, H)
was corrected by an unbound fraction of the test compound in the
incubation medium (Kilford et al., 2008).
2.4. In vitro skin permeation
HWY/Slc rats were killed by CO2 gas. The abdominal skin was
carefully excised, and subcutaneous tissue was removed. Human
skin was thawed at room temperature and cut into the appropriate
size.
Franz-type diffusion cells with an effective diffusion area of
0.785 cm2 (radius: 0.5 cm) and a receptor cell volume of 5 ml were
used. Diffusion cells were ﬁlled with receptor ﬂuid (phosphate-
buffered saline containing 5 w/v% of bovine serum albumin). The
skin was set dermis-side down on the diffusion cell, and the
temperature of the receptor ﬂuid was controlled to maintain the
test system at 32 °C. Approximately 50 mg of each ointment was
applied to the skin surface. Receptor ﬂuid was sampled at 3, 18, 20,
22 and 24 h in HWY/Slc rat skin, and 3, 6, 18, 20, 22 and 24 h in
human skin after application. The sampling volume was 2 ml, and
2 ml of fresh receptor ﬂuid was added after each sampling.
2.5. Sample preparation for liquid chromatography coupled with
tandem mass spectrometry (LC-MS/MS) measurement
The concentrations of calcipotriol and maxacalcitol in the
samples were measured by LC-MS/MS. All samples were mixed
with ice-cold acetonitrile containing internal standard. After cen-
trifugation, the supernatant was collected and liquid-liquid ex-
traction by ethyl acetate was performed. The extract was evapo-
rated under nitrogen gas at 40 °C and reconstituted with metha-
nol/water/5 mol/l ammonium acetate/1 mol/l ammonium formate
(500/500/2/2, vol%) the same as the LC-MS/MS sample.
2.6. LC-MS/MS analysis
LC-MS/MS analyses were performed with the API5000 system
(AB SCIEX) coupled with the Agilent 1200 series HPLC system
(Agilent Technologies) and HTC PAL autosampler (CTC Analytics).
The Analyst software program (version 1.6.1) was used for the
calculation of the test compound concentrations in individual
samples.
An XBridge C18 column (3.5 mm, 4.6 mm I.D.100 mm, Wa-
ters) with OPTI-GUARD (C18, Optimize Technologies) was used as
the analytical column and the pre-column ﬁlter at room tem-
perature, respectively. The mobile phases were A: methanol/wa-
ter/5 mol/l ammonium acetate (200/800/2, v/v/v) and B:
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2, v/v/v) at a ﬂow rate of 0.6 ml/min. Chromatography of both
calcipotriol and maxacalcitol was performed under the following
gradient condition: 0–0.2 min 85% B, 0.2–3.5 min 85–100% B, 3.5–
5 min 100% B, and 5–7 min 85% B. The LC eluent was introduced
into the source using an electrospray ionization interface in the
positive ionization mode. Detected ions (Q1/Q3) of calcipotriol,
maxacalcitol, and simvastatin were m/z 395.3/133.2, 436.3/297.3,
and 419.3/285.1, respectively. Simvastatin was used as an internal
standard based on the protocol described in a previous report (Li
et al., 2013).
2.7. Statistical analysis
Bartlett's test was performed to test equality of variance. Mul-
tiple comparisons among each group were assessed by one-way
analysis of variance, followed by the Tukey test or Kruskal-Wallis
test, followed by the Steel-Dwass test. Values of Po0.05 were
considered to be statistically signiﬁcant. All statistical calculations
were performed using the Statistical Analysis System software
program (SAS; Release 9.2; SAS Institute, Cary, NC, USA).Fig. 2. Serum concentrations of VD3 analogues after topical application of max-
acalcitol, calcipotriol and calcipotriol/betamethasone ointments in rats. The serum
samples were collected at 1, 2, 6, 10, 24 and 48 h after the application of ointments.
In both calcipotriol- and calcipotriol/betamethasone-treated rats, the serum con-
centration of calcipotriol was below the lower limit of quantiﬁcation (0.1 ng/ml) at
all time points examined. Each point with a bar represents the mean7S.D. (n¼4).3. Results
3.1. Calcemic effects and systemic exposure of VD3 analogues after
the topical administration of VD3 ointments in rats
To evaluate the effects of VD3 analogue-containing ointments
on calcium homeostasis in rats, the serum concentration of cal-
cium was measured at 24 h after the topical application of max-
acalcitol ointment, calcipotriol ointment or calcipotriol/beta-
methasone ointment (Fig. 1). No signiﬁcant change in the serum
calcium level was observed in the rats treated with calcipotriol
ointment or calcipotriol/betamethasone ointment compared to the
sham-treated rats. On the other hand, the serum calcium level in
the rats treated with maxacalcitol ointment was signiﬁcantly
higher than that in the sham, calcipotriol ointment and calcipo-
triol/betamethasone ointment-treated rats.
As shown in Fig. 2, in both the calcipotriol ointment and cal-
cipotriol/betamethasone ointment-treated rats, the serum con-
centration of calcipotriol was below the lower limit of quantiﬁ-
cation (0.1 ng/ml) at all time points examined. On the other hand,
maxacalcitol in the serum was detected at 1, 2, 6 and 10 h, but not
at 24 and 48 h, after the topical application, and the maximum
serum concentration (Cmax) of maxacalcitol in rats treated with
maxacalcitol ointment was 0.28970.142 ng/ml. Thus, the serumFig. 1. Effects of maxacalcitol, calcipotriol and calcipotriol/betamethasone oint-
ments on the serum calcium level after topical application in rats. Sham-treated
rats were used as a control. Each column with a bar represents the mean7S.D.
(n¼4). ** Po0.01 (Tukey test).concentration of VD3 analogue in rats treated with maxacalcitol
ointment was higher than that in the rats treated with calcipotriol
ointment or calcipotriol/betamethasone ointment.
3.2. A pharmacokinetic study after intravenous administration of
calcipotriol and maxacalcitol in rats
The plasma pharmacokinetics of calcipotriol and maxacalcitol
were evaluated after a single intravenous administration to the
rats (Fig. 3(A) and (B)). After the intravenous administration of
calcipotriol at a dose of 1 mg/kg, the plasma concentration of
calcipotriol decreased monophasically. The t1/2, AUC0-1 and
CLplasma were 0.22970.021 h, 358782 ng h/ml and 2.8870.54 L/
h/kg, respectively. The plasma concentration of maxacalcitol also
decreased over time. The t1/2, AUC0-1 and CLplasma were
0.38370.012 h, 25907282 ng h/ml and 0.39070.042 L/h/kg, re-
spectively. These pharmacokinetic parameters are described in
Table 1.
3.3. In vitro metabolism
The metabolic stabilities of calcipotriol and maxacalcitol in the
rat and human cryopreserved hepatocytes were evaluated using a
substrate depletion approach (Fig. 4(A) and (B)). In rat hepato-
cytes, calcipotriol rapidly decreased compared with maxacalcitol,
and the CLint,H of calcipotriol and maxacalcitol were 2.0670.09
and 0.048570.0012 ml/min/106 cells, respectively. In human he-
patocytes, calcipotriol rapidly decreased as well, and the CLint,H
of calcipotriol and maxacalcitol were 1.4870.07 and 0.02087
0.0033 ml/min/106 cells, respectively. The CLint, H is described in
Table 1.
3.4. In vitro skin permeation
Skin permeation of VD3 analogue-containing ointment through
rat and human skins was evaluated using Franz-type diffusion
Fig. 3. Plasma concentration-time proﬁle of calcipotriol (A) and maxacalcitol (B) after single intravenous administration of calcipotriol or maxacalcitol to male rats at a dose
of 1 mg/kg. Each point with a bar represents the mean7S.D. (n¼4).
Table 1
Summery table of in vivo pharmacokinetic parameters after intravenous administration and in vitro metabolic clearance (CLint, H) in hepatocytes. Each values in the table
represent the mean7S.D. (n¼3–4).
Compound t1/2 (h) AUC0-1 (ng h/ml) CLplasma (L/h/kg) Rat CLint, H (ml/min/106 cells) Human CLint, H (ml/min/106 cells)
Calcipotriol 0.22970.021 358782 2.8870.54 2.0670.09 1.4870.07
Maxacalcitol 0.38370.012 25907282 0.39070.042 0.048570.0012 0.020870.0033
Fig. 4. Metabolic stabilities of calcipotriol and maxacalcitol in rat (A) and human (B) cryopreserved hepatocytes. Closed triangles and closed circles indicate maxacalcitol and
calcipotriol, respectively. Each point with a bar represents the mean7S.D. (n¼3). An exponential regression curve ﬁtted to the points is shown in the graph.
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analogues at 24 h after application through rat skin from max-
acalcitol, calcipotriol and calcipotriol/betamethasone ointments
were 4137140, 62.1730.4 and 203767 ng/cm2, respectively. The
cumulative amounts of permeated VD3 analogues at 24 h after
application through human skin from maxacalcitol, calcipotriol
and calcipotriol/betamethasone ointments were 93.0749.5,
10.278.4 and 15.379.0 ng/cm2, respectively. Thus, the skin per-
meability of maxacalcitol after the topical application of max-
acalcitol ointment was signiﬁcantly higher than that of calcipotriolafter the topical application of calcipotriol or calcipotriol/beta-
methasone ointment in rat and human skins.4. Discussion
The calcemic effects in psoriasis patients have been reported to
differ among ointments containing these VD3 analogues such as
tacalcitol, calcipotriol and maxacalcitol (Yamamoto et al., 2012).
However, the reason for such differences remains to be fully
Fig. 5. Cumulative amount permeated-time proﬁles of test compounds through rat (A) and human (B) skin from ointments. Closed triangles, closed circles and closed
squares indicate vitamin D analogues from maxacalcitol-, calcipotriol/betamethasone-, and calcipotriol-containing ointments, respectively. Each point with a bar represents
the mean7S.D. (n¼6). * Po0.05 (Kruskal-Wallis test, followed by Steel-Dwass test).
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mimic the clinical situation. Therefore, in this study, a potential
reason for the difference was evaluated according to their phar-
macokinetic proﬁles, including skin permeation and hepatocyte
metabolism.
Baroni et al. (2008) reported that rats are likely to be a relevant
species to predict an acute calcemic response of a VD3 analogue in
human. Therefore, the calcemic effects of VD3 analogue-containing
ointments in rats were evaluated in this study. Our present study
demonstrated that the calcemic effects of calcipotriol- and calci-
potriol/betamethasone-containing ointments were signiﬁcantly
lower than that of maxacalcitol-containing ointment (Fig. 1), and
that the Cmax of VD3 analogue in the rats treated with calcipotriol-
and calcipotriol/betamethasone-containing ointments was lower
than that in the rats treated with maxacalcitol-containing oint-
ment (Fig. 2). Based on our ﬁndings and the ﬁndings that binding
activities of metabolites of calcipotriol and maxacalcitol generated
by keratinocytes to vitamin D receptor are approximately two
orders of magnitude lower than their parent compounds (Masuda
et al., 1994; Masuda et al., 1996), these results suggest that high
systemic exposure of VD3 analogues therefore induces calcemic
effects in rats. These ﬁndings were supported by previous reports
which showed the serum calcium levels in rats after in-
traperitoneal or oral administration of VD3 analogues to increase
with the AUC and/or Cmax of VD3 analogues (Baroni et al., 2008;
Brown et al., 1993; Saito and Harada, 2014). Thus, high systemic
exposure of VD3 analogues is thought to be a relevant factor of
hypercalcemia in rats.
On the other hand, the concentration of VD3 analogues in the
skin has been suggested to play an important role in their efﬁcacy
(Morimoto et al., 1986). Although the amounts of VD3 analogues in
the skin was not measured in this study, it has been reported that
the amounts of maxacalcitol and calcipotriol in the skin of rats
treated with VD3 analogue-containing ointments were almost the
same (Yamaguchi et al., 2008). Based on our ﬁndings and those of
other previous reports which showed that tacalcitol, maxacalcitol
and calcipotriol suppressed the proliferation of keratinocytes with
a similar in vitro potency, the efﬁcacy of maxacalcitol and calci-
potriol in the skin was suggested to be comparable aftertransdermal dosing.
To understand the reason why the systemic exposure differed
among VD3 analogues, a pharmacokinetic study after intravenous
administration, hepatic metabolism studies, and skin permeation
studies were conducted. As shown in Fig. 3, the CLplasma of calci-
potriol in rats was much greater than that of maxacalcitol, and the
in vitro CLint, H in rat cryopreserved hepatocytes provided sup-
portive evidence of the in vivo clearance (Fig. 4(A)). Subsequently,
in the skin permeation study, the cumulative amounts of calci-
potriol permeated through rat skin applied with calcipotriol- and
calcipotriol/betamethasone-containing ointments were sig-
niﬁcantly lower than that of maxacalcitol permeated through rat
skin applied with maxacalcitol-containing ointments (Fig. 5(A)),
which were consistent with the results of previous reports (Ya-
maguchi et al., 2008). These results suggested that the lower
systemic exposure of calcipotriol in rats treated with calcipotriol-
and calcipotriol/betamethasone-containing ointments resulted
from the low skin permeability and the high metabolic clearance
in liver associated with calcipotriol. Interestingly, similar results
were observed in a study using human hepatocytes and human
skin (Figs. 4(B) and 5(B)), implying that the systemic exposure of
calcipotriol is probably low in humans as well as rats.
In general, the unbound fraction of the drug in plasma protein
(fu, p), as well as CLint, H, is an important factor affecting the in vivo
hepatic clearance (CLH) of drug because CLH is simply expressed by
fu, p and CLint, H (CLH¼fu, pCLint, H) (Riley et al., 2005). As pre-
viously reported, plasma VD3 interaction with vitamin D binding
protein (VDBP), which is involved in the disposition of plasma VD3,
was demonstrated using VDBP knockout mice, suggesting that
VDBP may be an important factor for the disposition of VD3 ana-
logues (Brown et al., 2013; Safadi et al., 1999). Indeed, the relative
afﬁnity of maxacalcitol to VDBP has been reported to be about
5 times less than that of calcipotriol (Dusso et al., 1991). This
ﬁnding could thus possibly explain the gap between CLint, H dif-
ference (CLint, H: 42-fold to fu, pCLint, H: 8.2-fold) and CLplasma
difference (7.4-fold) in the current study. Therefore, the hepatic
metabolic rate appears to be more dominant in VD3 disappearance
compared to VDBP interaction in the case of calcipotriol and
maxacalcitol.
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nation with ointments containing steroids for the treatment of
psoriasis. In addition, a combination ointment of calcipotriol and
betamethasone dipropionate has been developed and prescribed
for patients with psoriasis. In this study, we showed that there was
no difference in the calcemic effects between calcipotriol-con-
taining ointment and calcipotriol/betamethasone-containing
ointment in rats. In in vitro skin permeation studies, the skin
permeability of calcipotriol in humans was comparable between
these ointments, whereas the skin permeability of calcipotriol in
rats was higher for calcipotriol/betamethasone-containing oint-
ment. In general, VD3 analogues such as calcipotriol and max-
acalcitol have been shown to be metabolized in rat skin and hu-
man cultured keratinocytes (Yamaguchi et al., 2006, 2008). Beta-
methasone might therefore have a potential to affect the expres-
sion or activity of the enzyme which is responsible for the meta-
bolism of calcipotriol in the rat skin. Further investigation is
therefore needed to identify the mechanisms of the VD3 analogue
metabolism in the skin.
In conclusion, the current study indicated that the lower cal-
cemic effect of calcipotriol- and calcipotriol/betamethasone-con-
taining ointments is caused by the low systemic exposure of cal-
cipotriol based on its low skin permeability and rapid hepatic
elimination after topical application.References
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